Carisma TherapeuticsCARM
13F holders, Q4 2025 (December 31)7holders −26
2new positions
28sold out
$0.04avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Carisma Therapeutics Inc. (CARM) in their 13F filings, down 26 from Q3 2025. 2 opened new positions and 28 sold out. The largest holders were Merck & Co., Inc. ($63K), XTX Topco Ltd ($2K) and Empowered Funds, LLC ($1K).
- Company
- Carisma Therapeutics Inc.
- CUSIP
- 14216R101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2K |
| Exits | 28 | $430K |
All 13F filers, Q3 2025 → Q4 2025: 59,862 shares bought and 1,571,009 shares sold, net −1,511,147 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Merck & Co., Inc. | 0.02% | No change | 1,473,240 | $63K |
| XTX Topco Ltd | 0.00% | New | 40,097 | $2K |
| Empowered Funds, LLC | 0.00% | No change | 30,988 | $1K |
| Baader Bank Aktiengesellschaft | 0.00% | New | 19,515 | $517 |
| Union Bancaire Privee, UBP SA | 0.00% | Add +46.7% | 785 | $28 |
| IFP Advisors, Inc | 0.00% | No change | 206 | $9 |
| ORG Partners LLC | 0.00% | No change | 200 | $8 |
"% of holder's portfolio" is CARM's weight in each manager's 13F, not the share of Carisma Therapeutics Inc. the manager owns.